Skip to main content
Log in

Predictors for frequent esophageal dilations of benign peptic strictures

  • Esophageal, Gastric, And Duodenal Disorders
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Recurrence of esophageal peptic stricture necessitating repeated dilation treatments remains a problem for many patients despite optimal acid suppressive therapy. The factors associated with frequent relapses are poorly understood. We studied retrospectively a population of 58 patients with benign peptic strictures and dysphagia treated by esophageal dilation and followed for 66.5 ± 6.7 months. Data was collected for age, sex, heartburn, weight loss, esophagitis, Barrett's esophagus, number of dilation treatments during the first year of follow-up, frequency and number of subsequent dilation treatments, type of dilator used, and history of other concurrent treatments. Patients who lacked heartburn (P=0.007) or who reported a history of weight loss (P=0.006) at the time of their initial presentation required more frequent dilations during the first year of follow-up. The mean number of dilations in year 1 was 6.2 ± 0.9 for patients lacking heartburn versus 3.2 ± 0.5 for patients with heartburn (P=0.004), and 9.0 ± 1.8 for patients who reported weight loss versus 4.1 ± 0.5 (P=0.006) for those who did not. The patients requiring frequent treatment during their first year also required frequent subsequent dilations because of stricture recurrence (P<0.0001). We did not demonstrate any relationship between the other factors studied and treatment frequency. These observations suggest that patients who require frequent retreatment for recurrent peptic stricture are more likely to provide a history of weight loss and less likely to complain of heartburn at initial presentation. The pattern of frequent repeat dilation for recurrent peptic strictures is established during the first year of follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hildreth CT: Stricture of the esophagus. N Engl J Med Surg 10:235, 1821

    Google Scholar 

  2. Patterson DJ: Natural history of benign esophageal stricture treated by dilation. Gastroenterology 85:346–350, 1983

    Google Scholar 

  3. Ogilvie AL, Ferguson R, Atkinson M: Outlook with conservative treatment of peptic oesophageal stricture. Gut 21:23–25, 1980

    Google Scholar 

  4. Hands LJ, Dennison AR, Papavramidis S, McIntyre RL, Bishop H, Kettlewell MG: The natural history of peptic oesophageal stricture treated by dilation and anti-reflux therapy alone. Ann R Coll Surg Engl 71:306–309, 1989

    Google Scholar 

  5. Smith PM, Kerr GD, Cockell R, Ross BA, Bate CM, Brown P, Dronfield MW, Green JRB, Hislop WS, Theodossi A, McFarland RJ, Watts DA, Taylor MD, Richardson PDI, RESTORE Investigator Group: A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 107:1312–1318, 1994

    Google Scholar 

  6. Lanza FL, Graham DY: Bougienage is effective treatment for most benign esophageal strictures. JAMA 240:844–847, 1978

    Google Scholar 

  7. Flood CA: Bougienage therapy for constrictive esophagitis. Gastrointest Endosc 25:130–132, 1979

    Google Scholar 

  8. Wesdorp ICE, Bartelsman JFWM, Den Hartog Jager FCA, Huibregtse K, Tytgat GN: Results of conservative treatment of benign esophageal strictures: A follow-up study in 100 patients. Gastroenterology 82:487–493, 1982

    Google Scholar 

  9. Glick ME: Clinical course of esophageal stricture managed by bougienage. Dig Dis Sci 27:884–888, 1982

    Google Scholar 

  10. Buchin PJ, Spiro HM: Therapy of esophageal stricture: A review of 84 patients. J Clin Gastroenterol 3:121–128, 1981

    Google Scholar 

  11. Farup PG, Modalski B, Tholfsen JK: Long-term treatment with 300 mg of ranitidine once daily after dilation of peptic oesophageal strictures. Scand J Gastroenterol 27:594–598, 1992

    Google Scholar 

  12. Ferguson R, Dronfield MW, Atkinson M: Cimetidine in treatment of reflux oesophagitis with peptic stricture. BMJ 2:472–474, 1979

    Google Scholar 

  13. Hine KR, Rai K, Bari A, Lin AG, Theodossi A: Famotidine in benign stricture: A double-blind study. Gastroenterology 104:A100, 1993 (abstract)

    Google Scholar 

  14. Periagini R, Al Dabbagh M, Misiewicz J, Evans PF, Trotman IF: Effect of dilation of peptic esophageal stricture on gastroesophageal reflux dysphagia and stricture diameter. Dig Dis Sci 33:389–392, 1988

    Google Scholar 

  15. Heller SR, Fellows IW, Olgilvie AL, Atkinson M: Non-steroidal anti-inflammatory drugs and benign oesophageal stricture. Br Med J 285:167–168, 1982

    Google Scholar 

  16. Wilkins WE, Ridley MG, Pozniak AL: Benign stricture of the oesophagus: Role of non-steroidal anti-inflammatory drugs. Gut 25:478–480, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

H.G. Preiksaitis is a recipient of an Ontario Ministry of Health Career Scientist Award. This work was supported in part by the Medical Research Council of Canada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agnew, S.R., Pandya, S.P., Reynolds, R.P.E. et al. Predictors for frequent esophageal dilations of benign peptic strictures. Digest Dis Sci 41, 931–936 (1996). https://doi.org/10.1007/BF02091533

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02091533

Key words

Navigation